Tag
A novel T classification system based on tumor invasion depth significantly improves prognostic stratification for biliary tract cancers around the cystic duct junction, unifying diverse cancer types under the junctional cholangiocarcinoma
A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
Final HERIZON‑BTC‑01 data show zanidatamab induces durable responses and a median overall survival of 15.5 months in previously treated HER2‑overexpressing metastatic biliary tract cancer, with greatest benefit in IHC 3+ tumors and manageab
Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explo
The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.
This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need
The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63%
A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.
The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.
A pooled analysis of NIFTY and NALIRICC trials demonstrates that liposomal irinotecan combined with 5-FU/leucovorin significantly improves progression-free survival and response rates in previously treated biliary tract cancer, with notable
This observational study reveals stable global biliary tract cancer mortality rates over two decades, with a striking rise in intrahepatic cholangiocarcinoma mortality, underscoring the need for targeted screening and management strategies.
